当前位置:首页 > 报告详情

Beam JPM deck_FINAL WEBSITE_260111.pdf

上传人: 明**** 编号:1069690 2026-01-17 27页 2.53MB

1、The Power of PredictabilityJANUARY 2026NASDAQ:BEAMCautionary note regarding forward-looking statementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.Such forward-looking statements include statements regarding:the ther

2、apeutic applications and potential of our technology,including with respect to SCD,AATD,GSDIa and beta-thalassemia;our plans,and anticipated timing,to advance our programs,including the clinical trial designs and expectations for risto-cel,BEAM-103,BEAM-301 and BEAM-302;our plans and anticipated tim

3、ing to present data from ongoing clinical trials;our anticipated regulatory interactions and filings;our current expectations and anticipated results of operations,including our expected use of capital;the sufficiency of our capital resources to fund operating expenses and capital expenditure requir

4、ements and the period in which such resources are expected to be available;and the therapeutic applications and potential of our technology,including our potential to develop lifelong,curative,precision genetic medicines for patients through base editing,including potential safety advantages,all of

5、which are subject to known and unknown important risks,uncertainties and other factors that may cause our actual results,performance or achievements,market trends,or industry results to differ materially from those expressed or implied by such forward-looking statements.Therefore,any statements cont

6、ained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such.Without limiting the foregoing,the words anticipate,expect,suggest,plan,vision,“strategy,”“possibility,”“promise,”believe,intend,project,forecast,estimates,targets,projections,po

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **公司愿景与技术**:Beam致力于通过精准基因编辑技术提供终身治愈疗法,聚焦罕见和常见疾病,技术优势包括低基因毒性和可预测的治疗效果。 2. **核心项目进展**: - **BEAM-302(AATD)**:临床数据显示总AAT均值12.4μM(超保护阈值11μM),Z-AAT降低78%,计划2026年Q1更新数据并推进关键试验。 - **Risto-cel(SCD)**:制造流程优化(中位2.9个月),计划2026年提交BLA,潜在最佳同类疗法。 - **BEAM-301(GSDIa)**:2026年报告初步临床数据。 3. **财务与战略**:现金储备12.5亿美元(2025年底),运营资金可支撑至2029年,通过合作获得超9亿美元非稀释性资金。
**基因编辑前景?** **BEAM-302疗效如何?** **SCD疗法有何突破?**
客服
商务合作
小程序
服务号
折叠